Effects of Antihypertensive Drugs and Gene Variants in the Renin-Angiotensin System.

• KATSUYA Tomohiro

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• IWASHIMA Yoshio

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• SUGIMOTO Ken

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• MOTONE Motoharu

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• ASAI Takashi

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• FUKUDA Masayuki

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• FU Yuxiao

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• HATANAKA Yasuko

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• OHISHI Mitsuru

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• RAKUGI Hiromi

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• HIGAKI Jitsuo

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

• OGIHARA Toshio

  Department of Geriatric Medicine, Osaka University Graduate School of Medicine

抄録

Many genes and environmental factors are involved in the pathogenesis of hypertension, but the exact cause of essential hypertension has not yet been clarified. Gene polymorphism of the renin-angiotensin system (RAS) is one of the candidates. In the current study, we examined whether there was a correlation between the gene polymorphisms in RAS and either the choice of antihypertensive drugs or their efficacy. Subjects with essential hypertension (n=299) were recruited from among the outpatients of Osaka University Hospital and provided their informed consent for genetic analysis. Physicians freely chose the antihypertensive drugs and adjusted its dose until the patient’s blood pressure was well controlled. The efficacy of each antihypertensive drug was estimated using the following formula: ΔBP=BP 1 (before treatment) - BP 2 (after treatment)/BP 1×100(%). Gene variants in RAS were determined using PCR or PCR-RFLP (restriction fragment of polymorphism). The gene polymorphism of RAS were not associated with ΔSBP or ΔDBP. However, the mean ΔSBP in subjects with a deletion homozygote of the angiotensin converting enzyme gene (ACE/DD) was significantly lower (p<0.05) than that in patients with an insertion/allele of the ACE gene. The gene polymorphisms of RAS did not significantly affect the choice of antihypertensive drugs. Even though gene polymorphism in the renin angiotensin system was not a major factor in the anti-hypertensive therapy, the determination of genotype might be of help in the management of essential hypertension. (Hypertens Res 2001; 24: 463-467)

収録刊行物

• Hypertension Research

  Hypertension Research 24 (4), 463-467, 2001

  日本高血圧学会

キーワード

• genetics
• pharmacogenetics
• gene polymorphism
• essential hypertension

詳細情報

• CRID: 1390282679696959744
• NII論文ID: 10009564630
• NII書誌ID: AA10847079
• DOI: 10.1291/hypres.24.463
• COI: 1:CAS:528:DC%2BD3MXmslWns7Y%3D
• ISSN: 13484214
• ISSN: 09169636
• ISSN: http://id.crossref.org/issn/09169636
• PubMed: 11510761
• Web Site: https://search.jamas.or.jp/link/ui/2002031477
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可